Leerink Partners Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $102

Benzinga · 07/10 20:41
Leerink Partners analyst Faisal Khurshid maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $88 to $102.